Serenatis Bio
Biotechnology Research
Cambridge, Cambridgeshire, United Kingdom
6 employees
- Employees
- 6
Serenatis Bio Overview
- Headquarters
- Cambridge, Cambridgeshire, United Kingdom
- Website
- www.serenatisbio.com
- Industry
- Biotechnology Research
- Employees
- 6
- Founded
- 2024
- Funding
- 53
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
About Serenatis Bio
Serenatis Bio is a start-up biotech developing three novel drugs to treat obsessive-compulsive disorder (OCD), a common yet poorly treated and devastating mental illness with huge unmet need and commercial opportunity. Each drug has a different mechanism of action - targeting glutamate and dopamine receptors - using precision medicine to identify which OCD patients will respond to which drug.
Compare Similar Companies to Serenatis Bio
Zinc
Venture Capital And Private Equity Principals
Novaterra
Holding Companies
Peripear Ltd
Technology, Information And Internet
Sterling Bio Machines
Pharmaceutical Manufacturing
Zonder
Health And Human Services
Cellestial Health
Biotechnology Research
GutSee Health
Biotechnology Research
Cambridge Medixine Ltd.
Biotechnology Research
Joey
Health And Human Services
P53
Investment Management